Reading the tape
NASDAQ: NVIV
InVivo Therapeutics Holdings Corporation
Healthcare · Biotechnology
Market Cap
$995.92K
52w High
$2.40
52w Low
$0.22
P/E
-0.05
Volume
1.61M
Outstanding Shares
3.11M
Not enough data to analyse price vs. fundamentals for this ticker.
Company profile
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI).
CEORichard M. Toselli
SectorHealthcare
IndustryBiotechnology
Employees6
IPO dateNov 15, 2010
Valuation
Forward P/E—
EV/EBITDA1.19
Enterprise value-$11.79M
Stock splits
Apr 27, 2022↓ Reverse
Every 25 shares became 1
Feb 12, 2020↓ Reverse
Every 30 shares became 1
Apr 17, 2018↓ Reverse
Every 25 shares became 1
Apr 8, 2015↓ Reverse
Every 4 shares became 1
Profitability & growth
Revenue growth—
Gross margin0%
Operating margin0%
ROE-64.64%▼18.38%vs FY2021
Analyst consensus
RatingBuy
Target price—
3
Buy
0
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Feb 14, 2024
Q1 FY24 · EPS est — · Revenue est —
View